INR 156.86
(2.0%)
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2023 | 248.6 Million INR | -30.25% |
2022 | 356.44 Million INR | -42.13% |
2021 | 615.9 Million INR | -25.73% |
2020 | 829.28 Million INR | 39.5% |
2019 | 594.48 Million INR | -5.34% |
2018 | 628 Million INR | 7.92% |
2017 | 581.92 Million INR | 48.89% |
2016 | 390.85 Million INR | 28.2% |
2015 | 304.86 Million INR | 28.49% |
2014 | 237.27 Million INR | -15.7% |
2013 | 281.47 Million INR | 7.22% |
2012 | 262.52 Million INR | 80.56% |
2011 | 145.39 Million INR | -32.17% |
2010 | 214.36 Million INR | -9.22% |
2009 | 236.14 Million INR | 0.14% |
2008 | 235.82 Million INR | 15.2% |
2007 | 204.7 Million INR | 0.0% |
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2024 Q1 | -655.85 Million INR | -363.82% |
2023 Q2 | 268.74 Million INR | 0.0% |
2023 FY | 248.6 Million INR | -30.25% |
2023 Q1 | - INR | -100.0% |
2023 Q3 | - INR | -100.0% |
2023 Q4 | 248.6 Million INR | 0.0% |
2022 Q2 | 709.85 Million INR | 0.0% |
2022 Q1 | - INR | -100.0% |
2022 FY | 356.44 Million INR | -42.13% |
2022 Q4 | 356.44 Million INR | 0.0% |
2022 Q3 | - INR | -100.0% |
2021 FY | 615.9 Million INR | -25.73% |
2021 Q1 | - INR | -100.0% |
2021 Q4 | 615.9 Million INR | 0.0% |
2021 Q3 | - INR | -100.0% |
2021 Q2 | 1.01 Billion INR | 0.0% |
2020 Q3 | - INR | -100.0% |
2020 Q4 | 829.28 Million INR | 0.0% |
2020 Q1 | - INR | -100.0% |
2020 Q2 | 765.18 Million INR | 0.0% |
2020 FY | 829.28 Million INR | 39.5% |
2019 Q3 | - INR | -100.0% |
2019 Q1 | - INR | -100.0% |
2019 FY | 594.48 Million INR | -5.34% |
2019 Q2 | 697.35 Million INR | 0.0% |
2019 Q4 | 594.48 Million INR | 0.0% |
2018 Q1 | - INR | -100.0% |
2018 Q3 | - INR | -100.0% |
2018 Q4 | 628 Million INR | 0.0% |
2018 FY | 628 Million INR | 7.92% |
2018 Q2 | 578.46 Million INR | 0.0% |
2017 Q2 | 518.19 Million INR | 0.0% |
2017 FY | 581.92 Million INR | 48.89% |
2017 Q3 | - INR | -100.0% |
2017 Q4 | 581.92 Million INR | 0.0% |
2017 Q1 | - INR | -100.0% |
2016 Q2 | 352.93 Million INR | 0.0% |
2016 Q3 | - INR | -100.0% |
2016 Q4 | 390.85 Million INR | 0.0% |
2016 FY | 390.85 Million INR | 28.2% |
2016 Q1 | - INR | -100.0% |
2015 Q1 | - INR | -100.0% |
2015 FY | 304.86 Million INR | 28.49% |
2015 Q4 | 304.86 Million INR | 0.0% |
2015 Q3 | - INR | -100.0% |
2015 Q2 | 430.82 Million INR | 0.0% |
2014 Q3 | - INR | -100.0% |
2014 Q2 | 247.52 Million INR | 0.0% |
2014 Q1 | - INR | -100.0% |
2014 FY | 237.27 Million INR | -15.7% |
2014 Q4 | 237.27 Million INR | 0.0% |
2013 Q3 | - INR | -100.0% |
2013 FY | 281.47 Million INR | 7.22% |
2013 Q1 | - INR | -100.0% |
2013 Q4 | 281.47 Million INR | 0.0% |
2013 Q2 | 334.1 Million INR | 0.0% |
2012 FY | 262.52 Million INR | 80.56% |
2012 Q2 | 219.3 Million INR | 0.0% |
2012 Q3 | - INR | -100.0% |
2012 Q4 | 262.52 Million INR | 0.0% |
2011 FY | 145.39 Million INR | -32.17% |
2011 Q4 | 145.39 Million INR | 0.0% |
2010 FY | 214.36 Million INR | -9.22% |
2009 FY | 236.14 Million INR | 0.14% |
2008 FY | 235.82 Million INR | 15.2% |
2007 FY | 204.7 Million INR | 0.0% |
Name | Total Liabilities | Total Liabilities Difference |
---|---|---|
Sigachi Industries Limited | 2.53 Billion INR | 90.179% |
Ind-Swift Limited | 13.45 Billion INR | 98.152% |
Bajaj HealthCare Limited | 4.86 Billion INR | 94.893% |
Sakar Healthcare Limited | 1.26 Billion INR | 80.321% |
Aurobindo Pharma Limited | 152.2 Billion INR | 99.837% |
Innova Captab Limited | 4.89 Billion INR | 94.926% |
Divi's Laboratories Limited | 18.99 Billion INR | 98.691% |
AstraZeneca Pharma India Limited | 3.66 Billion INR | 93.21% |
Morepen Laboratories Limited | 4.45 Billion INR | 94.426% |
Mankind Pharma Limited | 23.87 Billion INR | 98.959% |
Sequent Scientific Limited | 8.27 Billion INR | 96.995% |
Wanbury Limited | 3.15 Billion INR | 92.122% |
Laurus Labs Limited | 42.71 Billion INR | 99.418% |
Nectar Lifesciences Limited | 11.21 Billion INR | 97.784% |
Glenmark Life Sciences Limited | 5.18 Billion INR | 95.202% |
Alembic Limited | 1.43 Billion INR | 82.641% |
Hikal Limited | 12.99 Billion INR | 98.087% |
Alembic Pharmaceuticals Limited | 16.27 Billion INR | 98.472% |
Neuland Laboratories Limited | 5.49 Billion INR | 95.479% |
J. B. Chemicals & Pharmaceuticals Limited | 10.7 Billion INR | 97.678% |
Glenmark Pharmaceuticals Limited | 65.11 Billion INR | 99.618% |
IOL Chemicals and Pharmaceuticals Limited | 6.32 Billion INR | 96.072% |
Themis Medicare Limited | 1.88 Billion INR | 86.829% |
RPG Life Sciences Limited | 1.38 Billion INR | 81.988% |
Zydus Lifesciences Limited | 71.79 Billion INR | 99.654% |
Lupin Limited | 96.23 Billion INR | 99.742% |
Amrutanjan Health Care Limited | 783.82 Million INR | 68.284% |
Wockhardt Limited | 39.87 Billion INR | 99.376% |
Vaishali Pharma Limited | 371.16 Million INR | 33.021% |
Aarti Pharmalabs Limited | 8.25 Billion INR | 96.987% |
Jagsonpal Pharmaceuticals Limited | 296.76 Million INR | 16.228% |
Jubilant Pharmova Limited | 61.27 Billion INR | 99.594% |
FDC Limited | 3.7 Billion INR | 93.298% |
Dr. Reddy's Laboratories Limited | 106.96 Billion INR | 99.768% |
Kilitch Drugs (India) Limited | 643.88 Million INR | 61.39% |
Eris Lifesciences Limited | 38.26 Billion INR | 99.35% |
Venus Remedies Limited | 1.39 Billion INR | 82.151% |
ZIM Laboratories Limited | 2.08 Billion INR | 88.052% |
Bliss GVS Pharma Limited | 2.1 Billion INR | 88.212% |
Par Drugs and Chemicals Limited | 159.79 Million INR | -55.579% |
Caplin Point Laboratories Limited | 3.5 Billion INR | 92.908% |
Shilpa Medicare Limited | 12.93 Billion INR | 98.078% |
Albert David Limited | 1.15 Billion INR | 78.384% |
Ajanta Pharma Limited | 10.71 Billion INR | 97.679% |
Hester Biosciences Limited | 3.59 Billion INR | 93.084% |
Suven Pharmaceuticals Limited | 2.03 Billion INR | 87.779% |
Solara Active Pharma Sciences Limited | 14.09 Billion INR | 98.236% |
Gufic Biosciences Limited | 5.59 Billion INR | 95.561% |
Windlas Biotech Limited | 1.76 Billion INR | 85.897% |
Procter & Gamble Health Limited | 2.56 Billion INR | 90.294% |
Aarey Drugs & Pharmaceuticals Limited | 1.72 Billion INR | 85.565% |
Mangalam Drugs & Organics Limited | 1.97 Billion INR | 87.421% |
Granules India Limited | 22.95 Billion INR | 98.917% |
Aarti Drugs Limited | 11.5 Billion INR | 97.839% |
Bal Pharma Limited | 2.51 Billion INR | 90.101% |
Alkem Laboratories Limited | 48.6 Billion INR | 99.489% |
Sun Pharmaceutical Industries Limited | 183.56 Billion INR | 99.865% |
Lincoln Pharmaceuticals Limited | 1.07 Billion INR | 76.865% |
Medicamen Biotech Limited | 940.36 Million INR | 73.563% |
Unichem Laboratories Limited | 8.06 Billion INR | 96.919% |
Bafna Pharmaceuticals Limited | 652.27 Million INR | 61.887% |
Biofil Chemicals and Pharmaceuticals Limited | 288.79 Million INR | 13.919% |
Valiant Laboratories Limited | 1.05 Billion INR | 76.509% |
Orchid Pharma Limited | 3.84 Billion INR | 93.533% |
Medico Remedies Limited | 438.24 Million INR | 43.273% |
Ind-Swift Laboratories Limited | 2.28 Billion INR | 89.142% |
Ipca Laboratories Limited | 33.74 Billion INR | 99.263% |
Syncom Formulations (India) Limited | 1.16 Billion INR | 78.665% |
Piramal Enterprises Limited | 560.47 Billion INR | 99.956% |
Torrent Pharmaceuticals Limited | 82.05 Billion INR | 99.697% |
NATCO Pharma Limited | 10.53 Billion INR | 97.64% |
Suven Life Sciences Limited | 148.62 Million INR | -67.272% |
Krebs Biochemicals & Industries Limited | 2.97 Billion INR | 91.641% |
Strides Pharma Science Limited | 37.68 Billion INR | 99.34% |
Indoco Remedies Limited | 10.34 Billion INR | 97.596% |
Alpa Laboratories Limited | 307.12 Million INR | 19.055% |
Lasa Supergenerics Limited | 541.92 Million INR | 54.126% |
Sun Pharma Advanced Research Company Limited | 3.89 Billion INR | 93.614% |